Department of Psychological and Brain Sciences, Boston University, 64 Cummington Mall, Boston, MA, 02215, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY, 40536, USA.
Psychopharmacology (Berl). 2017 Oct;234(19):2897-2909. doi: 10.1007/s00213-017-4681-y. Epub 2017 Jul 20.
Research with the spontaneously hypertensive rat (SHR) model of attention deficit/hyperactivity disorder demonstrated that chronic methylphenidate treatment during adolescence increased cocaine self-administration established during adulthood under a progressive ratio (PR) schedule. Compared to vehicle, chronic atomoxetine treatment during adolescence failed to increase cocaine self-administration under a PR schedule in adult SHR.
We determined if enhanced noradrenergic transmission at α2-adrenergic receptors within prefrontal cortex contributes to this neutral effect of adolescent atomoxetine treatment in adult SHR.
Following treatment from postnatal days 28-55 with atomoxetine (0.3 mg/kg) or vehicle, adult male SHR and control rats from Wistar-Kyoto (WKY) and Wistar (WIS) strains were trained to self-administer 0.3 mg/kg cocaine. Self-administration performance was evaluated under a PR schedule of cocaine delivery following infusion of the α2-adrenergic receptor antagonist idazoxan (0 and 10-56 μg/side) directly into prelimbic cortex.
Adult SHR attained higher PR break points and had greater numbers of active lever responses and infusions than WKY and WIS. Idazoxan dose-dependently increased PR break points and active lever responses in SHR following adolescent atomoxetine vs. vehicle treatment. Behavioral changes were negligible after idazoxan pretreatment in SHR following adolescent vehicle or in WKY and WIS following adolescent atomoxetine or vehicle.
α2-Adrenergic receptor blockade in prelimbic cortex of SHR masked the expected neutral effect of adolescent atomoxetine on adult cocaine self-administration behavior. Moreover, greater efficacy of acute idazoxan challenge in adult SHR after adolescent atomoxetine relative to vehicle is consistent with the idea that chronic atomoxetine may downregulate presynaptic α2A-adrenergic autoreceptors in SHR.
使用注意缺陷多动障碍(ADHD)的自发性高血压大鼠(SHR)模型进行的研究表明,在成年期间使用递增比率(PR)方案进行慢性哌甲酯治疗会增加成年期间建立的可卡因自我给药。与载体相比,在成年 SHR 中,青春期使用慢性阿托西汀治疗并未在 PR 方案下增加可卡因自我给药。
我们确定前额叶皮层中 α2-肾上腺素能受体的增强去甲肾上腺素传递是否有助于解释青春期阿托西汀治疗对成年 SHR 的中性作用。
在使用阿托西汀(0.3mg/kg)或载体治疗后,从出生后第 28-55 天开始,成年雄性 SHR 和来自 Wistar-Kyoto(WKY)和 Wistar(WIS)品系的对照大鼠接受 0.3mg/kg 可卡因的自我给药训练。在直接向额前皮质输注 α2-肾上腺素能受体拮抗剂伊达唑兰(0 和 10-56μg/侧)后,根据可卡因输送的 PR 方案评估自我给药表现。
成年 SHR 达到了更高的 PR 断点,并且与 WKY 和 WIS 相比,有更多的主动杠杆反应和注射次数。与青春期使用载体相比,伊达唑兰在青春期使用阿托西汀治疗的 SHR 中剂量依赖性地增加了 PR 断点和主动杠杆反应。在青春期使用载体或在青春期使用阿托西汀或载体治疗的 WKY 和 WIS 后,伊达唑兰预处理对 SHR 几乎没有行为改变。
在 SHR 的额前皮质中阻断 α2-肾上腺素能受体掩盖了青春期阿托西汀对成年可卡因自我给药行为的预期中性作用。此外,与青春期使用载体相比,青春期使用阿托西汀治疗的 SHR 中急性伊达唑兰挑战的更高功效与慢性阿托西汀可能下调 SHR 中突触前 α2A-肾上腺素能自身受体的观点一致。